Winlet Pharmaceuticals (Pvt) Ltd.
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore pharmaceutical manufacturer established in 2009 with allopathic, nutraceutical and skincare product lines.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Winlet Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 73/G, Johar Town, Lahore 54000, Pakistan · 54000
- Website
- winletpharma.com ↗
- Phone
- +92 321 8420799
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| AIRRIO | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 30ml | 092022 | PKR 187.97 | PKR 6.27/mL | 13% above median |
| Amarus | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 12.5 mg + 160 mg | Tablet | 14'S | 104831 | PKR 286.03 | PKR 20.43/tablet | No comparator |
| Amarus | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 12.5 mg + 160 mg | Tablet | 28'S | 117810 | PKR 310.84 | PKR 11.10/tablet | 20% below median |
| Amarus | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 12.5 mg + 160 mg | Tablet | 14'S | 117810 | PKR 155.42 | PKR 11.10/tablet | 20% below median |
| Antilept | Levetiracetam | 100 mg/mL | Syrup | 15ml | 092027 | PKR 208.86 | PKR 13.92/mL | 11% above median |
| Antilept | Levetiracetam | 100 mg/mL | Syrup | 120ml | 092027 | PKR 1,503.73 | PKR 12.53/mL | Near median |
| Antilept | Levetiracetam | 100 mg/mL | Syrup | 60ml | 092027 | PKR 751.87 | PKR 12.53/mL | Near median |
| Antilept | Levetiracetam | 100 mg/mL | Syrup | 30ml | 092027 | PKR 396.82 | PKR 13.23/mL | 6% above median |
| Antilept | Levetiracetam | 500 mg | Tablet | 10'S | 104837 | PKR 991.07 | PKR 99.11/tablet | Near median |
| Antilept | Levetiracetam | 250 mg | Tablet | 10'S | 104845 | PKR 596.91 | PKR 59.69/tablet | 8% above median |
| Blaise 40mg Injection IVRegistry verified | Esomeprazole as sodium | — | — | — | 108400Official source ↗ | No indexed price | — | — |
| Brent | Levofloxacin | 500 mg | Tablet | 10'S | 092039 | PKR 746.14 | PKR 74.61/tablet | 6% below median |
| Brent | Levofloxacin | 250 mg | Tablet | 10'S | 092040 | PKR 448.40 | PKR 44.84/tablet | 7% below median |
| Bruflet | Ibuprofen | 200 mg/5 mL | Suspension | 90ml | 092031 | PKR 107.62 | PKR 1.20/mL | 6% below median |
| Bruflet | Ibuprofen | 200 mg/5 mL | Suspension | 60ml | 092031 | PKR 71.75 | PKR 1.20/mL | 6% below median |
| Bruflet | Ibuprofen | 100 mg/5 mL | Suspension | 90ml | 092032 | PKR 73.10 | PKR 0.81/mL | 14% below median |
| Camay | Cefixime | 400 mg | Capsule | 5'S | 104804 | PKR 546.99 | PKR 109.40/capsule | Near median |
| Camay | Cefixime | 100 mg/5 mL | Suspension | 30ml | 104805 | PKR 305.25 | PKR 10.18/mL | Near median |
| Camay | Cefixime | 200 mg/5 mL | Suspension | 30ml | 104806 | PKR 373.56 | PKR 12.45/mL | 8% below median |
| Cilara | Ciprofloxacin | 750 mg | Tablet | 10'S | 096583 | PKR 412.52 | PKR 41.25/tablet | Near median |
| Cilara | Ciprofloxacin | 250 mg | Tablet | 10'S | 096584 | PKR 233.17 | PKR 23.32/tablet | 8% below median |
| Cilara | Ciprofloxacin | 500 mg | Tablet | 10'S | 096585 | PKR 385.63 | PKR 38.56/tablet | 10% below median |
| Clarlet | Clarithromycin | 250 mg/5 mL | Dry suspension | 60ml | 094250 | PKR 660.05 | PKR 11.00/mL | 6% below median |
| Clarlet | Clarithromycin | 125 mg/5 mL | Dry suspension | 60ml | 094251 | PKR 399.97 | PKR 6.67/mL | 9% below median |
| Clarlet | Clarithromycin | 250 mg | Tablet | 10'S | 104843 | PKR 457.96 | PKR 45.80/tablet | Near median |
| Clarlet | Clarithromycin | 500 mg | Tablet | 10'S | 104847 | PKR 763.27 | PKR 76.33/tablet | 9% below median |
| Diego | Cholecalciferol | 5 mg/mL | Injection | 5'Amp's | 104814 | PKR 891.12 | — | No comparator |
| Diego | Cholecalciferol | 5 mg/mL | Injection | 1 Amp | 104814 | PKR 209.90 | PKR 209.90/vial/unit | Near median |
| Donato | Olanzapine | 3 mg | Capsule | 14'S | 092059 | PKR 271.50 | PKR 19.39/capsule | No comparator |
| Donato | Olanzapine | 6 mg | Capsule | 14'S | 092060 | PKR 455.29 | PKR 32.52/capsule | Near median |
| Donato | Olanzapine | 12 mg | Capsule | 10'S | 092061 | PKR 543.02 | PKR 54.30/capsule | 6% above median |
| Dtan 10 | Amlodipine + Olmesartan | 10 mg + 40 mg | Tablet | 20's | 116519 | PKR 1,606.17 | PKR 80.31/tablet | No comparator |
| Dtan 5 | Amlodipine + Olmesartan | 5 mg + 20 mg | Tablet | 20's | 116518 | PKR 967.91 | PKR 48.40/tablet | No comparator |
| Ferolet | Iron | 50 mg/5 mL | Syrup | 120ml | 104840 | PKR 261.80 | PKR 2.18/mL | 9% below median |
| Ferolet | Iron | 50 mg/5 mL | Syrup | 60ml | 104840 | PKR 133.57 | PKR 2.23/mL | 7% below median |
| Ferolet-FA | Iron | 100 mg | Tablet | 30'S | 098494 | PKR 423.30 | PKR 14.11/tablet | 15% above median |
| Fibi | Terbinafine | 125 mg | Tablet | 10's | 116550 | PKR 439.07 | PKR 43.91/tablet | 19% below median |
| Fibi | Terbinafine | 250 mg | Tablet | 10's | 116551 | PKR 701.39 | PKR 70.14/tablet | 17% below median |
| Funcona | Fluconazole | 50 mg/5 mL | Dry suspension | 35ml | 092023 | PKR 376.66 | PKR 10.76/mL | 9% below median |
| Funcona | Fluconazole | 150 mg | Capsule | 1'S | 092055 | PKR 247.52 | PKR 247.52/capsule | 6% below median |
| Funcona | Fluconazole | 200 mg | Capsule | 4'S | 092056 | PKR 860.93 | PKR 215.23/capsule | 8% below median |
| Igner | Irbesartan | 300 mg | Tablet | 10'S | 104820 | PKR 706.27 | PKR 70.63/tablet | 18% above median |
| Imipehz | Imipenem + Cilastatin | 250 mg + 250 mg | Injection | Vial | 109530 | PKR 1,708.73 | PKR 1,708.73/vial/unit | No comparator |
| Itrawin | Itraconazole | 100 mg | Capsule | 4'S | 107046 | PKR 572.45 | PKR 143.11/capsule | Near median |
| Kasen | Ketoconazole | 200 mg | Tablet | 10'S | 104819 | PKR 403.26 | PKR 40.33/tablet | No comparator |
| Klancy | Clomifene citrate | 50 mg | Tablet | 10'S | 107987 | PKR 412.16 | PKR 41.22/tablet | Near median |
| Laurent 10 | Amlodipine + Valsartan | 10 mg + 160 mg | Tablet | 14'S | 107988 | PKR 847.93 | PKR 60.57/tablet | 30% above median |
| Laurent 5 | Amlodipine + Valsartan | 5 mg + 160 mg | Tablet | 14'S | 107989 | PKR 722.62 | PKR 51.62/tablet | 23% above median |
| Laurent 5 | Amlodipine + Valsartan | 5 mg + 80 mg | Tablet | 14'S | 107990 | PKR 505.43 | PKR 36.10/tablet | 21% above median |
| Leep | Letrozole | 2.5 mg | Tablet | 10'S | 092050 | PKR 4,177.03 | PKR 417.70/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.